10. Rossolini GM, Mantengoli E.

Treatment and control of severe infections caused by

multiresistant Pseudomonas aeruginosa. Clin Microbiol Infect 2005; Nr.11(Suppl. 4), p. 17
31.
11. Goossens H. Susceptibility of multi-drug-resistant Pseudomonas aeruginosa in intensive care
units: results from the European MYSTIC study group. Clin Microbiol Infect 2003, Nr. 9, p.
980-3
12. . ., . ., . . .

// . 005. . 50. . . 41.

13. Podschun R, Ullmann U (). "Klebsiella spp. as nosocomial pathogens: epidemiology,
taxonomy, typing methods, and pathogenicity factors". Clin Microbiol Rev 1998, Nr.11 (4),
p. 589603.
14. Smith J M B, Chambers S T. Klebsiella oxytoca revealing decreased susceptibility to
extended spectrum beta-lactams. J Antimicrob Chemother. 1995; Nr.36, p. 265267.
15. A Krmr, Ir S, Gr Km. H somial pathogens
persist on inanimate surfaces? A systematic review. BMC Infect Dis. 2006; Nr.6, p130.
16. Rozalski, A., Z. Sidorezyk, and K. Kotelko. Potential virulence factors of Proteus bacilli.
Microbiol. Mol. Biol. Rev. 1997. Nr.61, p.65-89.
17. Madigan MT, Martinko JM Brock Biology of microorganisms. 11th. Pearson, 2006.
18. Feng P, Weagant S, Grant, M Enumeration of Escherichia coli and the Coliform Bacteria.
Bacteriological Analytical Manual (8th ed.). FDA/Center for Food Safety & Applied
Nutrition (2002).

PARTICULARITA ILEDE AC IUNEABENZITURONULUI PE FONDAL DE

BLOCARE ADRENERGIC
Tatiana Chiriac
Catedra Frm Frm , USMF N Tsm

The benzyturon showed a pronounced hypotensive effect on the fondale of -

Summary

adrenoblocking action propranolol.

Br msr s r -
Rezumat

adrenoblocantului propranolol.

Introducere
U rr mr m mr s r r r noi
ss mms rs, r r, r
r msrrr, s r rsm m. Nmrs
s rm mr rm r rsi arteriale pentru reducerea
mr mr rsr. M s m r m r
rs mrs r r, r r, sr r r
rs, m r r r.
N r r-r r-r (r) s s
ssrr s rr 1,,7, r ss rr-S-
r (r), rm sr- 1 suplimentat ulterior [4] a 18
ss (.1) msr sr rr s rs rr
r m (4-5ore).

277
 As m s r r r m
extinde ps rr rmr srr s rs
rr 4. O r rr r r r r rr
rrr , rr rs r r r r.

50
Presiunea arterial (mmHg)

40
30
20
10
0
-10
-20
-30
-40
Izoturon

LL-5

LL-35

LL-55

LL-36

LL-2

LL-175

LL-237

LL-22

LL-1

LL-53

LL-4

LL-54

LL-3

MM-1

MM-3

MM-2

Benzituron
Fig.1Repartizareasubstan elorchimicedup eficacitateascreening-ului farmacologic

Br s ss r r msm
rr rr rs s r m .
Pr rr rr r rm r rm r s
ss r m rr mms rs, s
m sr rs rr r. S rr
msr sr (s) r
fenilefrinei, efedrinei, angiotensinei II [4] .

Scopul studiului s r ss r sr PA FCC

fondal de blocare a receptorilor adrenergici cu propranolol- adrenoblocant neselectiv.

Materialeimetode. Er s 14 s ms rr -4 kg
s s 0 r (500 m/) r (50 m/), msr
intraperitoneal, ulterior cu monitorizarea PA, FCC la diferite intervale de timp.
S rr 0, m/ s msr rs rsrr
m 5, rm m 5 msrr rs s r
0,005 m/, r m/ 1,5 m sr rsrr
la anumite intervale de timp.

Rezultatele. D r r PA sr mrr rr,

m FCC s m r 6 /m (P0,05) - 5-a min. de la
msrr. Ir r 0,005 m/ s r
msr s rrr -adrenorgici. rm srr PA,
FCC s r (. 1). Ir rs rr
r rm smr mr PA rrs 0 m (.1).
r m FCC s rs m 15, m 0 r
r rs (.1). D m 60 PA s s mr mr - r
rsrr, PA s m 45mmH m m r .
D m s , PA s s mr, s s FCC (m 60).
As s r rr rm 0 m

278
 ms r s sr, 2-
rrrr sr rm mrr rs rr r 5.
m s r, , r, s m -adrenoblocantului manifestat prin
rsr FCC, r m rs sr r s mm r.
N s s ms sr r, rm r -
receptorilor. S- s NO ( r) sr mr mr
r 6. NO ate fi sintetizat de endoteliu coronarelor sau chiar cardiomiocite [6].
R s s m rs r sm rmr NO r
r NOS (r s): s, s , r r r de
sm r NO, s ms s r. D m
efectul cronotrop negativ al -r s mr NO
r s s s 0-60 m s s mifeste efectul
hipotensiv.

Discu ii. S r r r 7 rms s r s

r rmm msm r. Analizele din ultimii ani [2, 3, 8] au
msr r r r s r rs (NOS)
mr r NO, r r sr r
m sr msr sr. E r s s r
stimur NOS rmr NO, r msr
vasculare, cu relaxarea acesteea.

Concluzii
1. Br m/ r s r -
adrenoreceptorilor. Nemanifestarea efectul s r rm 0 m
r sr , s r sr
r, r r 1-adrenoreceptorilor cordului.
2. Tr s r r m r rigine reflectorie, deoarece nu se
r msrr s -adrenoblocantului.

Bibliografie
1. Dr V.V. Omr r rrr mm m r
r sr s rr , // Ar.
...m., C. 1998.
2. G V., Sr E., Tr. M. N ss ssrr r r
r, VIII Crs S Rm F, 5-7 m 000, I.
3. G V., Sr E., Tr. M. N rm rrr msm
r r r. A USMF N.Tsm , V. I. Prm m-
rm, E I. C 000, 18-19 octombrie, p. 182-187.
4. Cr T., G V., E rs r r HPT-49, Al VI
Crs N Frm,Tr T C, Rm, C-
Napoca, 8-11 iunie 2005, p. 78-84.
5. Frishman W. H., Alwarshetty M. -adrenergic blockers in systemic hypertension.
Pharmacologic considerations related to the current guidelines. Clin.Pharmacokinet., 2002;41
: 505-516.
6. Sr E. A mr msr r r r //
Arr ..m., C, 001, -23.
7. . .
. // . . . . , 1971 ..
8. Sr E., G V., Cr V. P r r rr sinergice de
r r sr. Cr . C, 00, .71-276.

279